ReviewBritish journal of clinical pharmacology2012
Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.
Review in British journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies.Clinical drug investigation · 2018Pooled it
- Drug disposition before and after gastric bypass: fenofibrate and posaconazole.British journal of clinical pharmacology · 2016Trial
- Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Trial
- Clinical evidence and biological mechanisms linking obesity to adverse outcomes in pediatric and adolescent acute lymphoblastic leukemia.Frontiers in oncology · 2026Review
- Pharmacokinetics and Childhood Obesity: Pathophysiological Basis and Challenges in Choosing the Ideal Body Size Descriptor.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Spotlight commentary: Changes in pharmacokinetics following significant weight loss.British journal of clinical pharmacology · 2025Article
- Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring Concentrations.Pharmaceutics · 2024Article
- Pharmacokinetics of single-dose rivaroxaban under fed state in obese vs. non-obese subjects: An open-label controlled clinical trial (RIVOBESE-PK).Clinical and translational science · 2024Article
- Management of femoral shaft infected nonunion through customised Ilizarov external fixator assembly in a morbidly obese patient.BMJ case reports · 2022Article
- The Impact of Diet and Exercise on Drug Responses.International journal of molecular sciences · 2021Review
- Article
- Modern pharmacological treatment of obese patients.Therapeutic advances in endocrinology and metabolism · 2020Review
- Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Article
- Impact of High Body Weight on Mortality in Critically Ill Patients Receiving Meropenem for Pneumonia.Cureus · 2019Article
- Propofol Sedation for Intragastric Balloon Removal: Looking for the Optimal Body Weight Descriptor.Obesity surgery · 2019Article
- Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study.Pharmacology research & perspectives · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The phenomena of hunger and need at one end of the spectrum and obesity and plenty on the other is an anomaly of the 21(st) century, likely to be due to a combination of distributive inequities in food, social justice, access to education and other socio-economic factors. Both are major problems worldwide, although obesity has more media coverage due to the exponentially increasing incidence and the huge social and economic burden this is placing on Western society. For example, prevalence rates of obesity are currently exceeding 30% of adults in the USA with direct morbidity and mortality complications, in addition to the additional obesity-related health problems and death. Obesity is also rising in children. Obese people are thus a sizable group, and as with those with altered renal or liver function, require specific consideration with respect to the appropriate dosing of medications. However guidelines for how to do this in obesity are not currently available, due to the paucity of literature and regulatory rules for new medications which usually only request the demonstration of average population effectiveness. We believe it is timely for regulatory agencies worldwide to mandate studies involving consideration of body size, particularly obesity, in approving new medications across the therapeutic spectrum. This will drive the pharmaceutical industry to consider these groups in studies and will encourage investigator-initiated research using therapeutic drug monitoring (TDM), target concentration therapy (TCI) and pharmacogenetic (PGx) studies to optimize drug dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.